Business
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
FOSTER CITY, Calif., April 17, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.
About this update from Gilead Sciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1728,"height":576,"url":"https://media.zenfs.com/en/business-wire.com/fedb1c64c8b0833a1df6c6d68bb04acd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V9rwNXpW8t3eGRN9bOiMLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/fedb1c64c8b0833a1df6c6d68bb04acd","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/77y6l3U1outkyxHdwjv9iQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA-/https://media.zenfs.com/en/business-wire.com/fedb1c64c8b0833a1df6c6d68bb04acd","width":1200,"height":400}},"lazy":false},{"type":"text","content":"FOSTER CITY, Calif., April 17, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.","length":343,"tagName":"p"},{"type":"text","content":"On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expiration of a 14-calendar day waiting period. Assuming that the ACCC’s determination remains unchallenged during this waiting period, the waiting period expires at 10:00 a.m., Eastern Time, on April 27, 2026. Additionally, the relevant review period for the Austrian competition authorities has expired. Accordingly, all required regulatory approvals for the transaction have been obtained, and the "Regulatory Approvals Condition" (as defined in the Offer to Purchase, dated March 6, 2026, relating to the offer) will be satisfied upon expiration of the 14-calendar day review period pursuant to Australian competition law.","length":803,"tagName":"p"},{"type":"text","content":"The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern Time, on April 24, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 27, 2026, and remains subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equal...